Use of neuraminidase inhibitors for prophylaxis and treatment of pandemic influenza: summary of a Faculty of Public Health meeting

被引:0
|
作者
Haroon, S. [1 ]
Middleton, J. [2 ]
Milne, E. M. G. [3 ]
机构
[1] Univ Birmingham, Inst Appl Hlth Res, Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England
[2] Wolverhampton Univ, Dept Publ Hlth, Wolverhampton WV1 1LY, W Midlands, England
[3] Univ Durham, Sch Med & Hlth, Durham DH1 3LE, England
关键词
communicable diseases; population-based and preventative services; public health; METAANALYSIS; OSELTAMIVIR; MORTALITY; ADULTS;
D O I
10.1093/pubmed/fdv196
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
On 15th December 2014, a meeting was held at the Faculty of Public Health (FPH) to gain views and where possible consensus on the prophylactic use among the general population of neuraminidase inhibitors (NIs) for pandemic influenza. These perspectives were to be used to help inform the FPH's position on current policy. This was felt to be necessary in response to the controversy that followed the publication of the updated Cochrane systematic review of the use of oseltamivir for seasonal influenza by Jefferson et al. (Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. 2014) and the disparate views held by members of the FPH on its implications for the relative benefits and harms of mass chemoprophylaxis for pandemic influenza.
引用
收藏
页码:E580 / E586
页数:7
相关论文
共 50 条
  • [31] Public prophylaxis: Pandemic influenza, pharmaceutical prevention and participatory governance
    Caduff, Carlo
    BIOSOCIETIES, 2010, 5 (02) : 199 - 218
  • [32] Pandemic influenza: A potential role for statins in treatment and prophylaxis
    Fedson, David S.
    CLINICAL INFECTIOUS DISEASES, 2006, 43 (02) : 199 - 205
  • [33] Use of Lean Response to Improve Pandemic Influenza Surge in Public Health Laboratories
    Isaac-Renton, Judith L.
    Chang, Yin
    Prystajecky, Natalie
    Petric, Martin
    Mak, Annie
    Abbott, Brendan
    Paris, Benjamin
    Decker, K. C.
    Pittenger, Lauren
    Guercio, Steven
    Stott, Jeff
    Miller, Joseph D.
    EMERGING INFECTIOUS DISEASES, 2012, 18 (01) : 57 - 62
  • [34] Trends of neuraminidase inhibitors use in children with influenza related respiratory infections
    Uda, Kazuhiro
    Okubo, Yusuke
    Shoji, Kensuke
    Miyairi, Isao
    Morisaki, Naho
    Michihata, Nobuaki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Yasunaga, Hideo
    PEDIATRIC PULMONOLOGY, 2018, 53 (06) : 802 - 808
  • [35] PANDEMIC INFLUENZA: MODELLING AND PUBLIC HEALTH PERSPECTIVES
    Arino, Julien
    Bauch, Chris
    Brauer, Fred
    Driedger, S. Michelle
    Greer, Amy L.
    Moghadas, Seyed M.
    Pizzi, Nick J.
    Sander, Beate
    Tuite, Ashleigh
    van den Driessche, P.
    Watmough, James
    Wu, Jianhong
    Yan, Ping
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2011, 8 (01) : 1 - 20
  • [36] Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care
    Da Silva, PR
    Nguyen-Van-Tam, JS
    Hayward, AC
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2003, 96 (02) : 66 - 69
  • [37] Neuraminidase Inhibitors in Influenza Treatment and Prevention-Is It Time to Call It a Day?
    Parra-Rojas, Cesar
    Van Kinh Nguyen
    Hernandez-Mejia, Gustavo
    Hernandez-Vargas, Esteban A.
    VIRUSES-BASEL, 2018, 10 (09):
  • [38] Neuraminidase inhibitors for treatment of equine influenza - when all else fails?
    Daly, J. M.
    VETERINARY JOURNAL, 2012, 193 (02): : 313 - 314
  • [39] Neuraminidase inhibitors for influenza A and B - Study showed benefits of treatment are marginal
    Oliver, M
    BRITISH MEDICAL JOURNAL, 2003, 327 (7406): : 105 - 105
  • [40] Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives
    Bassetti, Matteo
    Castaldo, Nadia
    Carnelutti, Alessia
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (14) : 1711 - 1718